241 related articles for article (PubMed ID: 30327963)
1. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
3. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
Zou B; Yeo YH; Jeong D; Park H; Sheen E; Lee DH; Henry L; Garcia G; Ingelsson E; Cheung R; Nguyen MH
Dig Dis Sci; 2020 May; 65(5):1520-1528. PubMed ID: 31598919
[TBL] [Abstract][Full Text] [Related]
4. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States.
Hirode G; Vittinghoff E; Wong RJ
J Clin Gastroenterol; 2019; 53(10):765-771. PubMed ID: 31135632
[TBL] [Abstract][Full Text] [Related]
5. Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis.
Barritt AS; Jiang Y; Schmidt M; Hayashi PH; Bataller R
Dig Dis Sci; 2019 Jun; 64(6):1460-1469. PubMed ID: 30673984
[TBL] [Abstract][Full Text] [Related]
6. Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.
Sayiner M; Otgonsuren M; Cable R; Younossi I; Afendy M; Golabi P; Henry L; Younossi ZM
J Clin Gastroenterol; 2017 Mar; 51(3):254-260. PubMed ID: 27332747
[TBL] [Abstract][Full Text] [Related]
7. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults.
Hirode G; Saab S; Wong RJ
JAMA Netw Open; 2020 Apr; 3(4):e201997. PubMed ID: 32239220
[TBL] [Abstract][Full Text] [Related]
8. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.
Younossi ZM; Zheng L; Stepanova M; Henry L; Venkatesan C; Mishra A
J Clin Gastroenterol; 2015 Mar; 49(3):222-7. PubMed ID: 24637730
[TBL] [Abstract][Full Text] [Related]
9. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample.
Hirode G; Vittinghoff E; Wong RJ
Dig Dis Sci; 2019 Jun; 64(6):1448-1457. PubMed ID: 30863953
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.
Reddy SK; Zhan M; Alexander HR; El-Kamary SS
World J Gastroenterol; 2013 Dec; 19(45):8301-11. PubMed ID: 24363521
[TBL] [Abstract][Full Text] [Related]
11. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
12. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
13. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
Hwang YC; Ahn HY; Park SW; Park CY
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
18. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
19. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
[TBL] [Abstract][Full Text] [Related]
20. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.
Sayiner M; Arshad T; Golabi P; Paik J; Farhat F; Younossi ZM
Hepatol Int; 2020 Jul; 14(4):556-566. PubMed ID: 32300995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
